Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study
暂无分享,去创建一个
C. Weenink | P. Bossuyt | P. Speelman | M. Bonten | P. Bresser | J. Poley | B. Opmeer | J. Prins | P. J. van den Broek | C. D. de Borgie | G. V. D. van den Berk | R. Moussaoui | B. V. D. van den Berg | W. Hustinx | F. Krouwels
[1] D. Snydman. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study , 2006, BMJ : British Medical Journal.
[2] J. Hermans,et al. Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia , 1995, European Journal of Clinical Microbiology and Infectious Diseases.
[3] M. Pichichero,et al. Metaanalysis of Short Course Antibiotic Treatment for Group A Streptococcal Tonsillopharyngitis , 2005, The Pediatric infectious disease journal.
[4] M. Bonten,et al. Revised SWAB guidelines for antimicrobial therapy of community-acquired pneumonia. , 2005, The Netherlands journal of medicine.
[5] H. Goossens,et al. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study , 2005, The Lancet.
[6] J. Rodenhiser,et al. Competing interests: None declared. , 2005 .
[7] P. Bossuyt,et al. Development and validation of a short questionnaire in community acquired pneumonia , 2004, Thorax.
[8] G. Agarwal,et al. Three day versus five day treatment with amoxicillin for non-severe pneumonia in young children: a multicentre randomised controlled trial , 2004, BMJ : British Medical Journal.
[9] Leon G Smith,et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] L. Hagberg,et al. Efficacy and Tolerability of Once-Daily Telithromycin Compared with High-Dose Amoxicillin for Treatment of Community-Acquired Pneumonia , 2002, Infection.
[11] Norbert Vetter,et al. A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia. , 2002, Clinical therapeutics.
[12] Pakistan Multicentre Amoxicillin Short Course Therapy pneum group. Clinical efficacy of 3 days versus 5 days of oral amoxicillin for treatment of childhood pneumonia: a multicentre double-blind trial , 2002, The Lancet.
[13] P. Nikolaides,et al. Randomized Controlled Trial of Sequential Intravenous (i.v.) and Oral Moxifloxacin Compared with Sequential i.v. and Oral Co-Amoxiclav with or without Clarithromycin in Patients with Community-Acquired Pneumonia Requiring Initial Parenteral Treatment , 2002, Antimicrobial Agents and Chemotherapy.
[14] G. Woods,et al. A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] O. Cars,et al. The Relationship between Antimicrobial Use and Antimicrobial Resistance in Europe , 2002, Emerging Infectious Diseases.
[16] O. Cars,et al. A European study on the relationship between antimicrobial use and antimicrobial resistance. , 2002, Emerging infectious diseases.
[17] W. Lim,et al. BTS Guidelines for the Management of Community Acquired Pneumonia in Adults , 2001, Thorax.
[18] C Peña,et al. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. , 2001, JAMA.
[19] J. Friend. Do smoking parents seek the best advice for their asthmatic children? , 2001, Thorax.
[20] M. Fine,et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. , 2001, American journal of respiratory and critical care medicine.
[21] P. Arvis,et al. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. , 2001, Chest.
[22] Michael J Fine,et al. Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] D. Felmingham,et al. The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. , 2000, The Journal of antimicrobial chemotherapy.
[24] O. Muller,et al. Randomized, Multicentre Study of the Efficacy and Tolerance of Azithromycin versus Clarithromycin in the Treatment of Adults with Mild to Moderate Community-Acquired Pneumonia , 1998, European Journal of Clinical Microbiology and Infectious Diseases.
[25] Claude Carbón,et al. Regulating the use of antibiotics in the community , 1998, BMJ.
[26] G. Gottlieb,et al. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[27] B. Balkau,et al. Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. , 1998, JAMA.
[28] P Huovinen,et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. , 1997, The New England journal of medicine.
[29] M. Fine,et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. , 1997, The New England journal of medicine.
[30] M. Rozenberg-Arska,et al. A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome. , 1997, International journal of antimicrobial agents.
[31] J. Klein,et al. Evaluation of New Anti-Infective Drugs for the Treatment of Respiratory Tract Infections , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[32] G. H. Ree,et al. Treatment of lobar pneumonia in Papua New Guinea: short course chemotherapy with penicillin or chloramphenicol. , 1983, The Journal of infection.
[33] A. Wicks,et al. One-day treatment for lobar pneumonia , 1970, Thorax.